Organ-sparing multimodality treatment for muscle-invasive bladder cancer: can we continue to ignore the evidence?
J Clin Oncol
.
2014 Dec 1;32(34):3787-8.
doi: 10.1200/JCO.2014.58.5521.
Epub 2014 Nov 3.
Authors
Claus Rödel
1
,
Christian Weiss
2
Affiliations
1
Goethe-University Frankfurt am Main, Frankfurt am Main, Germany claus.roedel@kgu.de.
2
Goethe-University Frankfurt am Main, Frankfurt am Main, Germany.
PMID:
25366679
DOI:
10.1200/JCO.2014.58.5521
No abstract available
Publication types
Editorial
Comment
MeSH terms
Carcinoma / therapy*
Cystectomy*
Female
Humans
Male
Muscle, Smooth / surgery*
Organ Sparing Treatments*
Urinary Bladder / surgery*
Urinary Bladder Neoplasms / therapy*
Grants and funding
U10 CA021661/CA/NCI NIH HHS/United States
U10 CA180822/CA/NCI NIH HHS/United States
U10 CA180868/CA/NCI NIH HHS/United States